Literature DB >> 18318728

Treatment of facial telangiectasia using a dual-wavelength laser system (595 and 1,064 nm): a randomized controlled trial with blinded response evaluation.

Syrus Karsai1, Susanne Roos, Christian Raulin.   

Abstract

BACKGROUND AND
OBJECTIVE: Pulsed dye (PDL) 595- and 1,064-nm Nd:YAG lasers are used for the treatment of vascular lesions. PDL-heated blood exhibits increased absorption of radiation at 1,064 nm, suggesting that the use of combined sequential dual wavelengths may offer benefits over single-wavelength treatments. This study compares the treatment efficacy of combined sequential dual-wavelength versus single delivery of 595-nm PDL or 1,064-nm Nd:YAG wavelengths in facial telangiectasia in a split face study design using subpurpuric parameters.
MATERIALS AND METHODS: Twenty patients were studied using the sequential delivery of PDL and Nd:YAG wavelengths on one side of the nose. The other side received either PDL or Nd:YAG treatment. Vessels (<0.6 mm in diameter) were treated with a 7-mm spot size at 10 J/cm(2), 10 ms with the PDL, followed by the Nd:YAG at 70 J/cm(2), 15 ms with a multiplex interpulse delay of 100 ms. Subjects received a single treatment, and results were evaluated after 4-week follow-up. Improvement was determined by blinded assessment of photographs taken before and after final evaluation.
RESULTS: The efficacy of the dual-wavelength laser treatment when compared to Nd:YAG or PDL laser alone was significantly more evident than either single-wavelength treatment (p<.05). There was no statistically significant difference in efficacy between the single-wavelength treatment groups.
CONCLUSION: The sequential delivery of 595- and 1,064-nm-wavelength radiation with an interpulse delay suggests that the synergistic approach to laser therapy for facial telangiectasia is a superior method compared to standard single wavelength therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18318728     DOI: 10.1111/j.1524-4725.2008.34131.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  [Non-pharmacologic management of rosacea].

Authors:  C Borelli; H C Korting
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

Review 2.  Laser and light-based therapies in the management of rosacea: an updated systematic review.

Authors:  Husein Husein-ElAhmed; Martin Steinhoff
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

Review 3.  [Innovations in dermatologic laser therapy].

Authors:  U Hohenleutner
Journal:  Hautarzt       Date:  2010-05       Impact factor: 0.751

4.  Treatment using a long pulsed nd:yag laser with a pulsed dye laser for four cases of blebbed port wine stains.

Authors:  Hee Sun Chang; Young-Gull Kim; June Hyunkyung Lee
Journal:  Ann Dermatol       Date:  2011-09-30       Impact factor: 1.444

Review 5.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

Review 6.  Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.

Authors:  E J van Zuuren; Z Fedorowicz; J Tan; M M D van der Linden; B W M Arents; B Carter; L Charland
Journal:  Br J Dermatol       Date:  2019-03-10       Impact factor: 9.302

7.  The Cost-Effectiveness of Pulsed-Dye Laser Therapy Among Thai Patients with Facial Port-Wine Stain: A Retrospective Study and Economic Evaluation.

Authors:  Rungsima Wanitphakdeedecha; Tatre Jantarakolica; Janice Natasha C Ng; Chadakan Yan; Yanisorn Nanchaipruek; Nuttagarn Jantanapornchai; Woraphong Manuskiatti; Tatchalerm Sudhipongpracha
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.